Alumis Inc.
ALMS
$4.28
-$0.03-0.70%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
4/10/2025
-
MarketBeat
4/24/2025
-
MarketBeat
4/23/2025
-
MarketBeat
4/22/2025
-
Ticker Report
4/22/2025
-
GuruFocus
4/22/2025
-
The Fly
4/21/2025
-
Ticker Report
4/21/2025
-
Seeking Alpha - Healthcare
4/21/2025
-
GuruFocus
4/21/2025
-
GuruFocus
4/21/2025
-
TipRanks Financial Blog
4/21/2025
-
GuruFocus
4/21/2025
-
GuruFocus
4/21/2025
-
GuruFocus
4/21/2025
-
The Fly
4/21/2025
-
Globe Newswire
4/21/2025
-
Globe Newswire
4/17/2025
-
Ticker Report
4/16/2025
-
Business Wire
4/12/2025
-
MarketBeat
4/7/2025
-
SeekingAlpha
4/5/2025
-
MarketBeat
4/5/2025
-
MarketBeat
4/5/2025
-
Simply Wall St
4/4/2025
-
GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, March 19, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Jun 2 and 6 (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
650 231 6625
Address
280 East Grand Avenue
South San Francisco, CA 94080
South San Francisco, CA 94080
Country
Year Founded
Business Description
Sector
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company’s clinical asset comprises ESK-001, an...
more